Statistics for Prostate Cancer

These statistics are from information published by the Surveillance, Epidemiology, and End Results (SEER) Program, a continuing project of the National Cancer Institute (NCI).

The SEER Program collects cancer data on a routine basis from designated population-based cancer registries in various areas of the country. Trends in cancer incidence, mortality and patient survival in the United States, as well as many other studies, are derived from this data bank.

Goals of the SEER Program include:

> Assembling and reporting, on a periodic basis, estimates of cancer incidence and mortality in the United States.

> Monitoring annual cancer incidence trends to identify unusual changes in specific forms of cancer occurring in population subgroups defined by geographic, demographic, and social characteristics.

> Providing continuing information on changes over time in the extent of disease at diagnosis, trends in therapy, and associated changes in patient survival.

> Promoting studies designed to identify factors amenable to cancer control interventions, such as:

a) environmental, occupational, socioeconomic, dietary, and health-related exposures

b) screening practices, early detection, and treatment

c) determinants of the length and quality of patient survival

NCI SEER Program - Information on prostate cancer in the United States from 1973 through 1995

African-American men have about a 60 percent higher incidence rate of prostate cancer than white men, and about a 2-fold higher mortality rate than white men.

Incidence rates increased 108 percent for white men from 1986 to 1992 and 102 percent for African-American men from 1986 to 1993. Increases in rates are believed to be related to use of the prostate-specific antigen (PSA) blood test as a new screening tool.

Recent treatment patterns for local/regional cancers vary by age:

  • Radical prostatectomy is more frequent among men under age 70.
  • Radiation therapy is more frequent in men ages 70 to 79.
  • Conservative therapy (no treatment or hormonal therapy) is more frequent in men over age 79.

Treatment for distant stage cancers has not changed over time - with about 65 percent of patients receiving hormonal therapy.

Based on cases diagnosed in 1990 and followed through 1995, 93 percent of all men diagnosed with prostate cancer will survive five years or longer.

The lowest incidence rates are found in Asians and Native Americans, and all other groups have lower rates than whites and blacks. The incidence rates peaked in 1992 for all groups except African-Americans, where it peaked in 1993.

Of patients with localized or regional stage prostate cancer, Native Americans have the poorest relative survival of all racial/ethnic groups. African-Americans and white-Hispanics have the lowest five-year relative survival rates among patients with distant stage disease.


Because prostate cancer is the number one incident cancer and the number two cause of cancer deaths among US men, these statistics are important for researchers, clinicians, policy makers, and citizens in understanding this disease.

UAB Health System
UAB Health System

UAB Health System

Physicians & Caregivers

Login